ZENAS BIOPHARMA INCZBIO
ASignal's systematic analysis rates ZBIO as Bearish.
Reflects the latest available analysis · analyzed Sep 12, 2026
The case on ZBIO
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Current price near lower Bollinger Band suggesting potential mean reversion
- High cash position with current ratio of 9.93x and quick ratio of 9.78x indicating strong liquidity
- Debt-to-equity ratio of 1.21x is manageable given cash reserves
- Negative MACD histogram indicating weakening momentum
- Price below SMA20 and SMA50 suggesting downtrend
- Extremely high price-to-sales ratio of 2028.30x and negative operating margin of -7765.90%
- Negative free cash flow of $-211.39M and negative operating cash flow of $-225.97M
- Negative return on equity (-199.04%) and negative return on assets (-34.42%)
- No Reddit mentions indicating lack of retail investor interest
See the full verdict on ZBIO
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes ZBIO
Most investors never get a second opinion, let alone several. ASignal runs ZBIO past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.